- KR₩439bn
- KR₩520bn
- KR₩247bn
Dyadic: Rises on expanding partnership to make COVID-19 vaccines for variants
Evolus: Brokerages hike PT on "win-win" settlement over Botox rival
Vaxine expects to start Phase II trials for potential COVID-19 vaccine in weeks
Brief: Medy Tox To Buy Back 10 Billion Won Worth Of Its Shares
Brief: Medy Tox To Invest 47.6 Billion Won To Build A New Production Line
Brief: Medy Tox to pay quarterly dividend at 900 won/share
Brief: Medy Tox to sell 1,968 shares at 613,100 won/share
Brief: Medy-Tox to pay annual cash dividend as 1,400 won/share
Brief: Medy Tox to buy back shares at 4.86 bln won
Brief: Medy Tox says quarterly cash dividend as 800 won/share
Brief: Medy-Tox to buy back shares at 5 bln won
Brief: Medy-Tox to dispose treasury shares for 1.53 bln won
Brief: Medy-Tox to buy back shares at 4.08 bln won
Brief: Medy-Tox says annual cash dividend for 2016
Brief: Medy-Tox to acquire properties for 82 bln won